$XBI $123.4 -1.41%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$HGEN -2.8% NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19. source
Pipeline Updates
$ANVS -19.0% Annovis Bio Pleased by Positive Interim Results from Ongoing Phase II Clinical Trials of ANVS401 (Posiphen) for the Treatment of Alzheimer's Disease and Parkinson's Disease. source
$IMAB +2.5% I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease. source
$AFMD -2.6% Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors. source
$TMDX -2.3% TransMedics Receives FDA Clearance of OCS Lung Solution for Cold Preservation of Lungs. source
$ERYP +55% On 7/29 ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL. source
$SAVA -32.7% On 7/29 Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease. source
$BCEL +11.8% On 7/29 Atreca Presents Initial Clinical Data from Phase 1b Trial of ATRC-101 in Select Advanced Solid Tumors. source
$BCLI +14.5% On 7/27 BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel. source
Financial Updates
$CRMD -2.7% Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of CorMedix Inc. (CRMD) Investors. source
$CERE -1.6% Cerevel Therapeutics Announces Redemption of Public Warrants. source
$IGMS On 7/29 IGM Biosciences Announces the Appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., as Chief Medical Officer. source
Posted by FS
Comments